vs
Cardio Diagnostics Holdings, Inc.（CDIO）与Celldex Therapeutics, Inc.（CLDX）财务数据对比。点击上方公司名可切换其他公司
Celldex Therapeutics, Inc.的季度营收约是Cardio Diagnostics Holdings, Inc.的33.8倍（$120.0K vs $3.6K）。Cardio Diagnostics Holdings, Inc.同比增速更快（-21.2% vs -89.8%）。Cardio Diagnostics Holdings, Inc.自由现金流更多（$-5.9M vs $-65.2M）。过去两年Celldex Therapeutics, Inc.的营收复合增速更高（-12.3% vs -52.8%）
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
CDIO vs CLDX — 直观对比
营收规模更大
CLDX
是对方的33.8倍
$3.6K
营收增速更快
CDIO
高出68.6%
-89.8%
自由现金流更多
CDIO
多$59.3M
$-65.2M
两年增速更快
CLDX
近两年复合增速
-52.8%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $3.6K | $120.0K |
| 净利润 | — | $-81.3M |
| 毛利率 | — | — |
| 营业利润率 | — | -72628.3% |
| 净利率 | — | -67764.2% |
| 营收同比 | -21.2% | -89.8% |
| 净利润同比 | 3.6% | -72.7% |
| 每股收益（稀释后） | — | $-1.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDIOCLDX
| Q4 25 | $3.6K | $120.0K | ||
| Q3 25 | $2.9K | $0 | ||
| Q2 25 | $7.5K | $730.0K | ||
| Q1 25 | $940 | $695.0K | ||
| Q4 24 | $4.5K | $1.2M | ||
| Q3 24 | $6.6K | $3.2M | ||
| Q2 24 | $7.9K | $2.5M | ||
| Q1 24 | $15.9K | $156.0K |
净利润CDIOCLDX
| Q4 25 | — | $-81.3M | ||
| Q3 25 | $-1.7M | $-67.0M | ||
| Q2 25 | $-1.7M | $-56.6M | ||
| Q1 25 | $-1.6M | $-53.8M | ||
| Q4 24 | — | $-47.1M | ||
| Q3 24 | $-1.4M | $-42.1M | ||
| Q2 24 | $-1.3M | $-35.8M | ||
| Q1 24 | $-4.2M | $-32.8M |
营业利润率CDIOCLDX
| Q4 25 | — | -72628.3% | ||
| Q3 25 | -59950.9% | — | ||
| Q2 25 | -22457.5% | -8747.5% | ||
| Q1 25 | -173463.8% | -9027.2% | ||
| Q4 24 | — | -4768.3% | ||
| Q3 24 | -21412.9% | -1633.5% | ||
| Q2 24 | -16295.6% | -1854.2% | ||
| Q1 24 | -26105.3% | -26030.8% |
净利率CDIOCLDX
| Q4 25 | — | -67764.2% | ||
| Q3 25 | -60053.8% | — | ||
| Q2 25 | -22517.7% | -7753.4% | ||
| Q1 25 | -173943.0% | -7740.4% | ||
| Q4 24 | — | -4007.8% | ||
| Q3 24 | -21467.6% | -1320.0% | ||
| Q2 24 | -16365.9% | -1434.8% | ||
| Q1 24 | -26140.0% | -21030.8% |
每股收益（稀释后）CDIOCLDX
| Q4 25 | — | $-1.23 | ||
| Q3 25 | $-0.98 | $-1.01 | ||
| Q2 25 | $-0.97 | $-0.85 | ||
| Q1 25 | $-0.97 | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | $-1.73 | $-0.64 | ||
| Q2 24 | $-1.71 | $-0.54 | ||
| Q1 24 | $-5.93 | $-0.56 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $518.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.0M | $527.2M |
| 总资产 | $7.8M | $583.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDIOCLDX
| Q4 25 | — | $518.6M | ||
| Q3 25 | — | $583.2M | ||
| Q2 25 | — | $630.3M | ||
| Q1 25 | — | $673.3M | ||
| Q4 24 | — | $725.3M | ||
| Q3 24 | — | $756.0M | ||
| Q2 24 | — | $802.3M | ||
| Q1 24 | — | $823.8M |
股东权益CDIOCLDX
| Q4 25 | $7.0M | $527.2M | ||
| Q3 25 | $8.2M | $598.4M | ||
| Q2 25 | $9.7M | $655.4M | ||
| Q1 25 | $11.4M | $703.0M | ||
| Q4 24 | $9.6M | $747.0M | ||
| Q3 24 | $3.7M | $785.9M | ||
| Q2 24 | $3.1M | $813.7M | ||
| Q1 24 | $3.0M | $838.6M |
总资产CDIOCLDX
| Q4 25 | $7.8M | $583.0M | ||
| Q3 25 | $8.8M | $648.4M | ||
| Q2 25 | $10.4M | $692.4M | ||
| Q1 25 | $12.3M | $739.5M | ||
| Q4 24 | $10.6M | $792.3M | ||
| Q3 24 | $4.5M | $823.2M | ||
| Q2 24 | $4.0M | $845.6M | ||
| Q1 24 | $4.3M | $868.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.7M | $-63.9M |
| 自由现金流经营现金流 - 资本支出 | $-5.9M | $-65.2M |
| 自由现金流率自由现金流/营收 | -166361.5% | -54350.8% |
| 资本支出强度资本支出/营收 | 5269.1% | 1067.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-10.5M | $-213.7M |
8季度趋势，按日历期对齐
经营现金流CDIOCLDX
| Q4 25 | $-5.7M | $-63.9M | ||
| Q3 25 | $-1.4M | $-48.6M | ||
| Q2 25 | $-1.6M | $-44.0M | ||
| Q1 25 | $-1.4M | $-54.4M | ||
| Q4 24 | $-5.0M | $-32.5M | ||
| Q3 24 | $-1.2M | $-55.3M | ||
| Q2 24 | $-1.2M | $-29.3M | ||
| Q1 24 | $-1.2M | $-40.6M |
自由现金流CDIOCLDX
| Q4 25 | $-5.9M | $-65.2M | ||
| Q3 25 | $-1.6M | $-49.1M | ||
| Q2 25 | $-1.6M | $-44.7M | ||
| Q1 25 | $-1.4M | $-54.6M | ||
| Q4 24 | $-5.2M | $-33.2M | ||
| Q3 24 | $-1.2M | $-55.9M | ||
| Q2 24 | $-1.4M | $-29.6M | ||
| Q1 24 | $-1.3M | $-41.0M |
自由现金流率CDIOCLDX
| Q4 25 | -166361.5% | -54350.8% | ||
| Q3 25 | -54509.7% | — | ||
| Q2 25 | -21273.1% | -6127.8% | ||
| Q1 25 | -149562.6% | -7861.4% | ||
| Q4 24 | -115422.6% | -2828.3% | ||
| Q3 24 | -17942.3% | -1751.2% | ||
| Q2 24 | -17513.3% | -1185.0% | ||
| Q1 24 | -7866.9% | -26270.5% |
资本支出强度CDIOCLDX
| Q4 25 | 5269.1% | 1067.5% | ||
| Q3 25 | 5703.5% | — | ||
| Q2 25 | 250.1% | 99.7% | ||
| Q1 25 | 615.6% | 38.1% | ||
| Q4 24 | 4759.9% | 64.3% | ||
| Q3 24 | 353.3% | 17.1% | ||
| Q2 24 | 2133.4% | 11.0% | ||
| Q1 24 | 125.5% | 220.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
